by Lyme Disease Treatment Market, By Disease Type (Early Lyme Disease, Lyme Carditis, Lyme Arthritis), By Treatment (Doxycycline, Amoxicillin, Cefuroxime Axetil) – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028.
Market Overview:
Lyme disease is a tick-borne infectious disease caused by the bacterium Borrelia burgdorferi. It is primarily transmitted if an infected black-legged ticks, which are commonly known as deer ticks bite a person. Lyme disease treatment typically involves the use of antibiotics to eliminate the bacterium Borrelia burgdorferi, which causes the infection. The choice of antibiotics and the duration of treatment depend on the stage of the disease and the severity of symptoms. Treatment is most effective when started early, during the early stages of the disease.
Competitive Landscape:
Major players operating in the global Lyme Disease Treatment Market include Hospira Inc., GlaxoSmithKline plc. , Sandoz AG, Teva Pharmaceutical Industries Ltd., G&W Laboratories, Inc., Pfizer Inc., Sun Pharmaceuticals Industries Ltd., Mylan N.V., and Lupin Ltd.
Key Market Drivers:
Global Lyme disease cases have been on the rise due to factors like climate change, growing tick population, and expanding habitats for disease-carrying ticks. This surge in the number of patients is driving the demand for effective treatment options. This is expected to augment the growth of the global Lyme disease treatment market. For instance, according to the Everyday Health Group, in 2021 around 14.5% of the global population was living with Lyme disease, or had been infected previously.
There have been significant advancements in the diagnosis and treatment of Lyme disease, including the development of new antibiotics and therapies. These innovations are positively impacting the growth of the market. Increasing awareness among the general population about Lyme disease symptoms and the importance of early diagnosis is leading to higher patient diagnosis rates, thus boosting the demand for treatments.
Governments across various regions are investing in Lyme disease research and promoting awareness campaigns. These initiatives are supporting market growth by facilitating research and development activities. The aging population is more susceptible to Lyme disease, and individuals with certain comorbidities, such as weakened immune systems, are at higher risk. This is estimated to enhance the growth of the global Lyme disease treatment market.
Covid-19 Impact Analysis:
During the COVID-19 pandemic, non-urgent medical visits and treatments were postponed or canceled, leading to delayed diagnosis and treatment of Lyme disease cases. The global disruptions in supply chains for pharmaceuticals and medical supplies during COVID-19 have affected the availability and distribution of Lyme disease treatments. Many research institutions and pharmaceutical companies shifted their focus and resources towards COVID-19 research, potentially diverting attention from Lyme disease research and development. This restrained the growth of the global Lyme disease treatment market.
The Mucopolysaccharidosis (MPS) Treatment Market is expected to witness significant growth, driven by the increasing focus on developing advanced products by companies.
Key Takeaways:
North America is expected to dominate the growth of the global Lyme Disease Treatment Market, owing to the high prevalence of Lyme disease in countries like the United States and Canada, as well as increased awareness and advanced healthcare infrastructure. For instance, according to the United States Centers for Disease Control and Prevention (CDC), around 20,000 to 30,000 cases of Lyme disease are reported every year in the United States.
The Asia Pacific is estimated to witness high growth in the global Lyme disease treatment market, primarily driven by changing climate conditions. Countries like China and Japan are expected to contribute to the market growth. For instance, according to The Economic Times, annually around 3000 to 5000 individuals in India are diagnosed with Lyme disease.
